More Awards for Monaghan Medical’s Aerobika® OPEP device!
The Aerobika® OPEP is a drug-free, handheld oscillating positive expiratory pressure (OPEP) device that has been uniquely designed to help you raise secretions. Exhale through the device, to expand your airways which will loosen mucus to be coughed up. The Aerobika® has received a 2017 Innovative Technology designation from Vizient, Inc., the largest member- driven healthcare performance improvement company in the country.
The Aerobika® has been shown to improve lung function, exercise capacity and quality of life in those with COPD and a real-world study showed that the device reduced exacerbation (flare up) rates. These improved outcomes (equivalent to six fewer exacerbations per 100 people per year) equal a cost savings of $553 per person with the Aerobika®. Study results appear in the October 20, 2017 issue of the International Journal of COPD. New data presented at CHEST 2017 also demonstrated that performance of the Aerobika® was superior to four other OPEP devices tested.
COPD is a major and growing source of healthcare utilization, with hospitalization for acute exacerbations being the biggest cost. Once a person experiences an exacerbation, the risk of repeat exacerbations is increased two to four times. Many experience two or three hospital admissions every year. As many as one in five discharged from hospital following an exacerbation are re-admitted within 30 days.
The cost of COPD in 2010 was estimated to be $50 billion – $30 billion in direct healthcare expenditure, with the remainder accounted for by indirect costs such as productivity losses and costs to families. Approximately $15 billion of the direct costs is due to hospital care for those with COPD exacerbations.